TAPI-2

Toxicity: Standard Handling (A)

A hydroxamate-based inhibitor of matrix metalloproteinases and TACE (TNF-α convertase; ADAM17). Inhibits the activation-dependent shedding of L-selectin from neutrophils, eosinophils, and lymphocytes as well as phenylarsine oxide (PAO)-induced shedding in neutrophils. Also blocks the shedding of several cell surface proteins such as pro-TGF-α, IL-6 receptor α-subunit, and β-amyloid precursor protein. Reported to inhibit TNF-α release and impart protection against aspirin-induced gastric mucosal injury. Acts as a weak inhibitor of angiotensin converting enzyme (IC₅₀ = 18 µM).

Bennett, T.A., et al. 2000. J. Immunol.164, 4120.
Fiorucci, S., et al. 1998. Aliment. Pharmacol. Ther.12, 1139.
Hooper, N.M., et al. 1997. Biochem. J.321, 265.
Parvathy, S., et al. 1997. Biochem. J.327, 37.
Arribas, J., et al. 1996. J. Biol. Chem.271, 11376.

Packaged under inert gas

A 10 mM (1 mg/241 µL) sterile-filtered solution of TAPI-2 (Cat. No. 579052) in H₂O.

Following initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 3 months at -20°C.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany